newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma to Present Data from Multiple Studies of Olverembatinib, Including the First Dataset from POLARIS-1 Study, at ASH 2025

  • Ascentage Pharma announced that data from multiple clinical studies of olverembatinib, lisaftoclax, & APG-5918 will be presented at the 67th American Society of Hematology (ASH) Annual Meeting in Orlando, Florida, from December 6-9, 2025.
  • Clinical data on olverembatinib has been selected for presentation at the ASH Annual Meeting for the eighth consecutive year.
  • The company will present the first dataset from the global Phase III POLARIS-1 study of olverembatinib combined with low-intensity chemotherapy for newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
  • Updated 4-year follow-up data from a registrational Phase II study of olverembatinib in tyrosine kinase inhibitor (TKI)-resistant chronic-phase chronic myeloid leukemia (CML-CP) will be reported.
  • Additional data on olverembatinib as a second-line treatment for non-T315I-mutant CML-CP will be presented at the meeting.
  • The POLARIS-1 study showed a 94.3% complete remission (CR) or CR with incomplete hematologic recovery rate by end of induction, with a 64.2% MRD-negative CR rate.
  • In the POLARIS-1 study, 90% of patients with high-risk IKZF1 plus genotypes achieved a molecular response at the end of induction therapy.
  • A registrational Phase II trial demonstrated that olverembatinib significantly improved event-free survival compared to best available therapy (BAT) in TKI-resistant CML-CP patients, with median EFS of 21.22 months vs 2.86 months.
  • Olverembatinib showed superior efficacy over BAT in CML-CP patients without T315I mutations, achieving 82.1% complete hematologic response & 25.8% complete cytogenetic response.
  • A single-arm study of olverembatinib as second-line therapy for CP-CML patients resistant to one prior TKI line showed response rates deepened over time, reaching 90.0% CCyR & 60.0% MMR by cycle 21.
  • The company highlighted favorable safety profiles for olverembatinib across studies, with hematologic toxicities being the most common adverse events.
  • Olverembatinib is the first China-approved third-generation BCR-ABL inhibitor & is currently being evaluated in three global registrational Phase III studies.
  • Lisaftoclax (APG-2575) & APG-5918 will also be featured in presentations, including data on lisaftoclax monotherapy for relapsed/refractory CLL/SLL & APG-5918 preclinical data for multiple myeloma.
  • Ascentage Pharma noted that olverembatinib, lisaftoclax, & APG-5918 are under investigation & have not yet received FDA approval in the US.